ArticleClinical and experimental medicine2014
Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer.
Article in Clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- CDK9 inhibition triggers MT2A-dependent apoptosis in HCC cells.Genes & genomics · 2026Article
- Gravitational forces and matrix stiffness modulate the invasiveness of breast cancer cells in bioprinted spheroids.Materials today. Bio · 2025Article
- Article
- Investigation of TNFα Level andArchives of Razi Institute · 2022Article
- Article
- Revisiting the metallothionein genes polymorphisms and the risk of oral squamous cell carcinoma in a Brazilian population.Medicina oral, patologia oral y cirugia bucal · 2021Article
- Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk.The Journal of international medical research · 2020Article
- Metallothionein 2A gene polymorphisms in relation to diseases and trace element levels in humans.Arhiv za higijenu rada i toksikologiju · 2020Review
- Polymorphisms inHereditary cancer in clinical practice · 2020Article
- Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray.Biomolecules · 2019Article
- Identification of XAF1-MT2A mutual antagonism as a molecular switch in cell-fate decisions under stressful conditions.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- Mammalian Metallothionein-2A and Oxidative Stress.International journal of molecular sciences · 2016Review
- The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective.International journal of molecular sciences · 2016Review
- Genetic variation in metallothionein and metal-regulatory transcription factor 1 in relation to urinary cadmium, copper, and zinc.Toxicology and applied pharmacology · 2015Article
- Metallothionein 2A core promoter region genetic polymorphism and its impact on the risk, tumor behavior, and recurrences of sinonasal inverted papilloma (Schneiderian papilloma).Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population.Medical oncology (Northwood, London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metallothioneins (MTs) are a family of metal binding proteins that play an important role in cellular processes such as proliferation and apoptosis. Metallothionein 2A is the most expressed MT isoform in the breast cells. A number of studies have demonstrated increased MT2A expression in various human tumors, including breast cancer. We carried out an association study to examine whether MT2A gene polymorphisms are associated with risk of breast cancer. Information on lifestyle risk factors was collected via a self-administered questionnaire. Genotyping was conducted using polymerase chain reaction-restriction fragment length polymorphism technique. Three single nucleotide polymorphisms (SNP) rs28366003, rs1610216 and rs10636 were genotyped in 534 breast cancer cases and 556 population controls. One SNP in MT2A (rs28366003) showed a positive association with breast cancer. Compared with homozygous common allele carriers, heterozygous for the G variant [odds ratio (OR) = 1.92, 95 % confidence interval (CI):1.28-2.81, p trend <0.01; the OR assuming a dominant model 1.93 (95 % CI: 1.29-2.89, (p dominant) <0.02) after adjustment for age, family history, smoking status, BMI, menarche, parity, menopausal status and use of contraceptive and menopausal hormones] had a significantly increased risk of breast cancer in Polish population, as well as women with haplotypes, including variant allele of rs28366003 SNP (OR = 1.58, CI: 0.41-6.33, p global = 0.03). Our data suggest that the rs28366003 SNP in MT2A is associated with risk of breast cancer in Polish population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.